EICHORCondition: Atrial Fibrillation, Persistent · Heart Failure · Sponsor: Second Xiangya Hospital of Central South University
Interested? Contact the study team ↓
This multicenter, randomized controlled trial aims to compare the clinical efficacy and safety of combining catheter ablation with Marshall vein ethanol ablation versus catheter ablation alone in patients with persistent atrial fibrillation (AF) and concomitant heart failure. Persistent AF is a common arrhythmia that significantly impacts the quality of life and survival rates, especially when coexisting with heart failure. While catheter ablation is a standard treatment for AF, its effectiveness in persistent AF, particularly in patients with heart failure, remains suboptimal. The addition of Marshall vein ethanol ablation may enhance treatment outcomes by targeting arrhythmogenic substrates. This study will enroll 120 participants across three centers to evaluate whether this combined approach can reduce AF recurrence, improve heart function, and enhance patient outcomes compared to catheter ablation alone.
This description comes directly from the study's public registry record.
Li Xuping · 3973183686 · lixp0711@126.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age between 18 and 80 years 2. For symptomatic patients with persistent atrial fibrillation: At least a 6-month history of atrial fibrillation; atrial fibrillation duration exceeding 7 days without spontaneous conversion to sinus rhythm; at least two episodes of persistent atrial fibrillation in the past 6 months even after rhythm conversion; poor tolerance or resistance to at least one Class I, II, or III antiarrhythmic drug 3. Diagnosed with heart failure: Echocardiogram showing left ventricular ejection fraction (LVEF) ≤40% 4. Patient willing to receive medication or surgical treatment 5. Patient willing to comply with the requirements before the study, during the study, and during follow-up and to sign an informed consent form 6. Capable of completing a 6-minute walk test 7. For women of childbearing potential, a negative pregnancy test result is required Exclusion Criteria: 1. Presence of thrombus in the left atrium 2. Left atrial diameter greater than 65 millimeters in the parasternal long-axis view, or left atrial volume exceeding 200 milliliters as measured by MRI or CT 3. Presence of significant congenital abnormalities or medical issues, deemed by the researcher as inappropriate for participation in the study 4. Reversible causes of atrial fibrillation, such as pericarditis, thyroid disease, acute alcohol intoxication, recent major surgery, or trauma 5. Currently suffering from valvular heart disease requiring surgical intervention 6. Currently suffering from coronary artery disease requiring surgical or percutaneous intervention 7. History of atrioventricular node ablation 8. Liver failure 9. Renal failure requiring dialysis 10. Contraindicated use of appropriate anticoagulation therapy 11. Participation in other experimental drug or device studies 12. Severe pulmonary disease 13. Previous catheter ablation for atrial fibrillation in the left atrium 14. Documented thromboembolic event within the past 90 days 15. Pregnant women
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06578793